Physician profile
Joel A Bezek
NPI 1780630798
$4,424.79
in general payments reported to CMS, 2019-2025
15 companies · $75.12 in 2025
The $75.12 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,754 · 2020: $130 · 2021: $73.01 · 2022: $237 · 2023: $89.04 · 2024: $67.12 · 2025: $75.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $3,485.05 | 2019 | |
| Alcon Vision LLC | $470.40 | 2019-2025 | Clareon, Centurion, Lensx |
| Biotissue Holdings INC. | $64.27 | 2019-2023 | |
| Abbvie INC. | $59.93 | 2024-2025 | |
| Carl Zeiss Meditec USA, INC. | $59.56 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $58.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $50.61 | 2020-2023 | |
| Allergan, INC. | $42.38 | 2019-2020 | |
| Oyster Point Pharma, INC. | $30.55 | 2022 | |
| Kedrion Biopharma, INC. | $24.93 | 2025 | Koate, Kedrab, Gammaked |
| Bausch & Lomb Americas INC. | $17.63 | 2023 | Vyzulta |
| Aerie Pharmaceuticals, INC. | $16.10 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.06 | 2021 | |
| New World Medical,INC. | $15.14 | 2023 | |
| Ocular Therapeutix, INC. | $13.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Bezek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.